Get the Stockscreener App
6.38
0.00%
0.00
After Hours:
6.39
0.010
+0.16%
Wave Life Sciences Ltd stock is traded at $6.38, with a volume of 2.44M.
It is up +0.00% in the last 24 hours and down -11.14% over the past month.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$6.38
Open:
$6.38
24h Volume:
2.44M
Relative Volume:
0.54
Market Cap:
$1.23B
Revenue:
$71.80M
Net Income/Loss:
$-183.59M
P/E Ratio:
-6.0514
EPS:
-1.0543
Net Cash Flow:
$-186.52M
1W Performance:
+3.91%
1M Performance:
-11.14%
6M Performance:
-16.82%
1Y Performance:
+7.23%
1-Day Range:
$6.225
$6.44
1-Week Range:
$6.02
$6.4999
52-Week Range:
$5.02
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
6.38 | 1.23B | 71.80M | -183.59M | -186.52M | -1.0543 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-26 | Initiated | BofA Securities | Buy |
| Dec-12-25 | Reiterated | Wedbush | Outperform |
| Dec-09-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-04-25 | Initiated | Canaccord Genuity | Buy |
| Jul-28-25 | Initiated | Oppenheimer | Outperform |
| Jul-16-25 | Initiated | Citigroup | Buy |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Wedbush | Outperform |
| Feb-25-25 | Initiated | Jefferies | Buy |
| Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
Should WVE-006’s RNA-Editing AAT Data Shift the Risk-Reward Calculus for Wave Life Sciences (WVE) Investors? - Yahoo Finance
Wave Life Sciences (WVE) Valuation Check After Sharp Share Price Weakness - simplywall.st
WAVE Life Sciences Analyst Ratings and Price Targets | NASDAQ:WVE - Benzinga
WVE Stock Price, Quote & Chart | WAVE LIFE SCIENCES LTD (NASDAQ:WVE) - ChartMill
Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Wave Life Sciences (WVE) Is Down 11.4% After Positive WVE-006 AATD Data and Accelerated Path Update - simplywall.st
Wave Life Sciences: 'Strong Buy' On DMD NDA Filing WVE-N531 And Released AATD Data - Seeking Alpha
WVE Maintained by Wells Fargo -- Price Target Raised to $14.00 - GuruFocus
Wave Life Sciences Is Maintained at Overweight by Wells Fargo - Moomoo
CCORF Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $43 - Moomoo
WVE: Advancing siRNA and RNA editing therapies with strong clinical data and regulatory momentum - TradingView
Wells Fargo raises Wave Life Sciences price target on AATD data - Investing.com Australia
Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $14 - Moomoo
Wave Life Sciences Signals Momentum in Earnings Call - TipRanks
Wave Life Sciences crashes deep into oversold territory as obesity drug data disappoints. Should you buy the dip? - MSN
WVE Maintained by HC Wainwright & Co. -- Price Target Lowered to $13 - GuruFocus
Wave Life Sciences' New Data From AATD Study Met Expectations, Wedbush Says - Moomoo
Cantor Fitzgerald reiterates Overweight on Wave Life Sciences stock By Investing.com - Investing.com South Africa
Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 - Yahoo Finance UK
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $13 to $15 - Moomoo
Wave Life Sciences stock price target lowered to $13 by H.C. Wainwright - Investing.com South Africa
Cantor Fitzgerald reiterates Overweight on Wave Life Sciences stock - Investing.com
H.C. Wainwright Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
Wave Life Sciences Announces Positive RestorAATion-2 Trial Results for WVE-006, a Novel RNA Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) - Minichart
Wave Life Sciences Ltd. (WVE) Shareholder/Analyst CallSlideshow (NASDAQ:WVE) 2026-05-18 - Seeking Alpha
WVE: WVE-006 delivers robust Z-AAT reduction and M-AAT restoration with strong safety in PiZZ AATD - TradingView
Wave Life Sciences reports phase 1b/2a trial data for AATD therapy By Investing.com - Investing.com South Africa
WVE: WVE-006 delivers robust, durable AAT correction and dynamic response in ZZ AATD with strong safety - TradingView
WVE Stock Edges Up After Positive Early Data For Rare Disease Drug - Stocktwits
WVE: WVE-006 achieved up to 71% Z-AAT reduction and restored protective M-AAT levels in AATD - TradingView
Wave Life Sciences advances WVE-006 RNA editing trial - TipRanks
Wave Life Sciences (WVE) Reports Progress on WVE-006 in Clinical Trial - GuruFocus
Wave Life Sciences reports phase 1b/2a trial data for AATD therapy - Investing.com
Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing - TradingView
WVE-006 AATD trial shows strong biomarker gains for Wave Life Sciences (WVE) - Stock Titan
Wave Life Sciences Reports Promising Data for WVE-006 in Treating Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency, Anticipates FDA Feedback in Mid-2026 - Quiver Quantitative
Experimental RNA-editing shot aims to treat lung and liver damage in alpha-1 - Stock Titan
Wave Life Sciences (WVE) price target decreased by 15.26% to 23.97 - MSN
Wave Life Sciences Ltd.Ordinary Shares (NQ: WVE - FinancialContent
Wedbush Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Wave Life Sciences ATS Data Could Support RNA Editing Platform, Wedbush Says - Moomoo
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight - GlobeNewswire Inc.
Wave Life Sciences stock (SG1V20936237): Starts Phase 1 trial for one-time GLP-1 gene therapy - AD HOC NEWS
Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times
Adage (NASDAQ: WVE) discloses 1,000,000-share stake, 0.53% of class - Stock Titan
Wave Life Sciences (WVE) Attracts Positive Attention Amid Compet - GuruFocus
Surging Q1 Revenue And Narrower Losses Might Change The Case For Investing In Wave (WVE) - Sahm
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Wave Life Sciences Ltd Stock (WVE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 27 '26 |
Buy |
6.43 |
2,495,623 |
16,046,856 |
26,004,414 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 30 '26 |
Buy |
6.50 |
971,091 |
6,312,092 |
26,975,505 |
| Francis Chris | See Remarks |
Feb 26 '26 |
Option Exercise |
4.28 |
33,194 |
141,920 |
79,767 |
| Francis Chris | See Remarks |
Feb 26 '26 |
Sale |
15.05 |
33,194 |
499,593 |
61,867 |
| Moran Kyle | Chief Financial Officer |
Feb 09 '26 |
Sale |
13.45 |
3,588 |
48,259 |
134,385 |
| BOLNO PAUL | President and CEO |
Feb 09 '26 |
Sale |
13.45 |
10,480 |
140,956 |
275,520 |
| Francis Chris | See Remarks |
Feb 09 '26 |
Sale |
13.45 |
1,883 |
25,326 |
61,867 |
| Vargeese Chandra | See Remarks |
Feb 09 '26 |
Sale |
13.45 |
3,228 |
43,417 |
408,246 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):